Phoenix Financial’s Protalix BioTherapeutics PLX Stock Holding History

Phoenix Financial’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92.9K	Hold	40,000	–	–	﹤0.01%	514
2026 Q1	$86.7K	Buy	+40,000	New	+$99.3K	﹤0.01%	479
2022 Q2	–	Sell	-244,113	Closed	-$259K	–	415
2022 Q1	$259K	Hold	244,113	–	–	﹤0.01%	349
2021 Q4	$203K	Hold	244,113	–	–	﹤0.01%	365
2021 Q3	$325K	Hold	244,113	–	–	0.01%	356
2021 Q2	$466K	Hold	244,113	–	–	0.01%	276
2021 Q1	$1.09M	Buy	+244,113	New	+$1.14M	0.02%	276
2020 Q4	–	Sell	-204,355	Closed	-$751K	–	415
2020 Q3	$751K	Buy	204,355 +16,019	+9%	+$57.9K	0.03%	216
2020 Q2	$681K	Buy	+188,336	New	+$644K	0.03%	226

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Phoenix Financial's PLX Position: Q2 2026 in Review

Phoenix Financial held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 40,000 shares worth $92.9K. The position accounts for ﹤0.01% of the portfolio, ranked #514.

Phoenix Financial first reported a position in PLX in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.09M in Q1 2021. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Phoenix Financial held 40,000 shares of Protalix BioTherapeutics worth $92.9K as of Q2 2026.
Phoenix Financial left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Phoenix Financial's portfolio in Q2 2026, its #514 holding.
Phoenix Financial first reported a position in Protalix BioTherapeutics in Q2 2020 and has held it in 9 quarters since.
Phoenix Financial's Protalix BioTherapeutics position peaked at $1.09M in Q1 2021.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Phoenix Financial's 13F filing for Q2 2026, filed 11 Aug 2026.